Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC ; volume:12 ; number:1 ; day:8 ; month:8 ; year:2022 ; pages:1-12 ; date:12.2022
Scientific reports ; 12, Heft 1 (8.8.2022), 1-12, 12.2022
- Urheber
-
Kunimasa, Kei
Nishino, Kazumi
Sato, Yoshiharu
Mori, Masahide
Ihara, Shoichi
Suzuki, Hidekazu
Nagatomo, Izumi
Kumagai, Toru
Morishima, Toshitaka
Imamura, Fumio
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-022-17848-y
- URN
-
urn:nbn:de:101:1-2022102423055081113638
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kunimasa, Kei
- Nishino, Kazumi
- Sato, Yoshiharu
- Mori, Masahide
- Ihara, Shoichi
- Suzuki, Hidekazu
- Nagatomo, Izumi
- Kumagai, Toru
- Morishima, Toshitaka
- Imamura, Fumio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases